Summary: the FLCCC issues a press release about the NIH reversal/relaxation on Ivermectin
In addition, they provide a link to their earlier pre-print (review of Ivermectin) - which they announce has been accepted for publication (see links below).
https://www.newswise.com/coronavirus/nih-revises-treatment-guidelines-for-ivermectin-for-the-treatment-of-covid-19/?article_id=744631
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)
15-Jan-2021
Newswise — NEW YORK, NEW YORK: —JANUARY 14, 2021: One week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC)— along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation on ivermectin, making it an option for use in COVID-19.
This new designation upgraded the status of ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation.
By no longer recommending against ivermectin use, doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA emergency use approval.
“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” noted Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.”
In its ivermectin recommendations update, the NIH also indicated they will continue to review additional trials as they are released. “We are encouraged that the NIH has moved off of its August 27 recommendation against the use of ivermectin for COVID-19,” continued Kory. “That recommendation was made just as the numerous compelling studies for ivermectin were starting to roll in. New studies are still coming in, and as they are received and reviewed, it is our hope that the NIH’s recommendation for the use of ivermectin will be the strongest recommendation for its use as possible.”
Current meta-analyses of studies of ivermectin from around the world show a compelling trend towards the drug’s potent benefits against SARS-CoV-2. Ivermectin, developed in 1975, led to the eradication of a “pandemic” of parasitic diseases across multiple continents and earned the 2015 Nobel Prize for Physiology or Medicine for its discoverers, Dr. William Campbell and Dr. Ōmura Satoshi.
In related news, the manuscript written by the FLCCC has been accepted for publication, following a rigorous peer review, in Frontiers in Pharmacology. The full paper will be published within the next couple of weeks, however the preview can be found here.
References mentioned above:
https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/
The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19
Last Updated: January 14, 2021
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Provisionally accepted
The final, formatted version of the article will be published soon.
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by
Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against COVID-19. They then identified repeated, consistent, large magnitude improvements in clinical outcomes in multiple, large, randomized and observational controlled trials in both prophylaxis and treatment of COVID-19. Further, data showing impacts on population wide health outcomes have resulted from multiple, large “natural experiments” that occurred when various city mayors and regional health ministries within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global solution to the pandemic. This was further evidenced by the recent incorporation of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Belize, Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210 million people. To our knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease phases. One limitation is that half the controlled trials have been published in peer-reviewed publications, with the remainder taken from manuscripts uploaded to medicine pre-print servers. Although it is now standard practice for trials data from pre-print servers to immediately influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID-19 infections.
[-] stereomatch | 4 points | Jan 15 2021 17:36:13
Summary: the FLCCC issues a press release about the NIH reversal/relaxation on Ivermectin
In addition, they provide a link to their earlier pre-print (review of Ivermectin) - which they announce has been accepted for publication (see links below).
https://www.newswise.com/coronavirus/nih-revises-treatment-guidelines-for-ivermectin-for-the-treatment-of-covid-19/?article_id=744631 NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Front Line COVID-19 Critical Care Alliance (FLCCC Alliance) 15-Jan-2021
Newswise — NEW YORK, NEW YORK: —JANUARY 14, 2021: One week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC)— along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation on ivermectin, making it an option for use in COVID-19.
This new designation upgraded the status of ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation.
By no longer recommending against ivermectin use, doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA emergency use approval.
“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” noted Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.”
In its ivermectin recommendations update, the NIH also indicated they will continue to review additional trials as they are released. “We are encouraged that the NIH has moved off of its August 27 recommendation against the use of ivermectin for COVID-19,” continued Kory. “That recommendation was made just as the numerous compelling studies for ivermectin were starting to roll in. New studies are still coming in, and as they are received and reviewed, it is our hope that the NIH’s recommendation for the use of ivermectin will be the strongest recommendation for its use as possible.”
Current meta-analyses of studies of ivermectin from around the world show a compelling trend towards the drug’s potent benefits against SARS-CoV-2. Ivermectin, developed in 1975, led to the eradication of a “pandemic” of parasitic diseases across multiple continents and earned the 2015 Nobel Prize for Physiology or Medicine for its discoverers, Dr. William Campbell and Dr. Ōmura Satoshi.
In related news, the manuscript written by the FLCCC has been accepted for publication, following a rigorous peer review, in Frontiers in Pharmacology. The full paper will be published within the next couple of weeks, however the preview can be found here.
References mentioned above:
https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/ The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19 Last Updated: January 14, 2021
https://www.frontiersin.org/articles/10.3389/fphar.2021.643369/abstract
Review Article
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Provisionally accepted
The final, formatted version of the article will be published soon.
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against COVID-19. They then identified repeated, consistent, large magnitude improvements in clinical outcomes in multiple, large, randomized and observational controlled trials in both prophylaxis and treatment of COVID-19. Further, data showing impacts on population wide health outcomes have resulted from multiple, large “natural experiments” that occurred when various city mayors and regional health ministries within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global solution to the pandemic. This was further evidenced by the recent incorporation of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Belize, Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210 million people. To our knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease phases. One limitation is that half the controlled trials have been published in peer-reviewed publications, with the remainder taken from manuscripts uploaded to medicine pre-print servers. Although it is now standard practice for trials data from pre-print servers to immediately influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID-19 infections.
permalink